Literature DB >> 8708548

IGF-I potentiates interleukin-2 production in human peripheral T cells.

R Kooijman1, G T Rijkers, B J Zegers.   

Abstract

IGF-I stimulates the proliferation and differentiation of many cell types. In the case of T cells, IGF-I has been described to potentiate mitogen-induced DNA synthesis. We have addressed the working mechanism of IGF-I on T cell proliferation by measuring the effects of IGF-I on various stages of T cell activation. We found that IGF-I augmented the phytohaemagglutinin- and anti-CD3-induced interleukin-2 (IL2) production of human peripheral T cells before they enter the S phase of the cell cycle. Furthermore, the addition of IGF-I did not influence DNA synthesis of IL2-dependent growing T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8708548     DOI: 10.1677/joe.0.1490351

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  6 in total

1.  Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes.

Authors:  Patrick T Walsh; Loraine M Smith; Rosemary O'Connor
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 3.  Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.

Authors:  Terry J Smith; Laszlo Hegedüs; Raymond S Douglas
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-06       Impact factor: 4.690

4.  Improvement of asymmetric thyroid eye disease with teprotumumab.

Authors:  Shoaib Ugradar; Yao Wang; Tunde Mester; George J Kahaly; Raymond Douglas
Journal:  Br J Ophthalmol       Date:  2021-02-12       Impact factor: 5.908

5.  Teprotumumab for thyroid eye disease: early response is not required for benefit.

Authors:  Shoaib Ugradar; Yao Wang; Tunde Mester; George J Kahaly; Raymond S Douglas
Journal:  Eye (Lond)       Date:  2021-06-28       Impact factor: 4.456

6.  Teprotumumab for the treatment of chronic thyroid eye disease.

Authors:  Shoaib Ugradar; Julia Kang; Andrea L Kossler; Erin Zimmerman; Jenna Braun; Andrew R Harrison; Swaraj Bose; Kimberly Cockerham; Raymond S Douglas
Journal:  Eye (Lond)       Date:  2021-07-09       Impact factor: 4.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.